Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Utilization of cardiovascular drugs in Zagreb 2001-2005 (CROSBI ID 238597)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Štimac, Danijela ; Polić-Vižintin, Marina ; Škes, Marija ; Cattunar, Albert ; Cerović, Robert ; Stojanović, Dražen Utilization of cardiovascular drugs in Zagreb 2001-2005 // Acta cardiologica, 65 (2010), 2; 193-201. doi: 10.2143/AC.65.2.2047053

Podaci o odgovornosti

Štimac, Danijela ; Polić-Vižintin, Marina ; Škes, Marija ; Cattunar, Albert ; Cerović, Robert ; Stojanović, Dražen

engleski

Utilization of cardiovascular drugs in Zagreb 2001-2005

The purpose of this study was to investigate the outpatient utilization of cardiovascular drugs in Croatia, during the period 2001-2005, using the Anatomical Therapeutic Chemical classification of drugs/Defined Daily Dose (ATC/DDD) methodology. Data on outpatient drug utilization were obtained from the Zagreb Municipal Pharmacy to calculate the number of defined daily dose (DDD), and DDD per 1000 inhabitants per day (DDD/1000/day). The drug utilization 90% (DU90%) method was used on drug prescribing quality assessment. Data on hospital admissions were collected from the inpatient database kept at the Zagreb Institute of Public Health. Total utilization of cardiovascular drugs (ATC group C), was between 402.9 Defined Daily Dose per 1000 inhabitants per day (DDD/TID) and 362.9 DDD/TID in Croatia between 2001 and 2005. Agents acting on the renin-angiotensin system (C09) (104.2 DDD/TID) and calcium channel blockers (C08) (80.5 DDD/TID) accounted for more than 50% of drugs used for the treatment of hypertension in 2005. A great increase in the utilization was observed for statins (78.3%). A markedly increasing utilization was recorded for angiotensin-converting enzyme (ACE) inhibitors in combination with hydrochlorothiazide (HCTZ) (40.5%) and angiotensin II antagonists (278%). Comparison of the DU90% segment between 2001 and 2005 revealed pentoxifylline and amiodarone to be absent, whereas cilazapril and ramipril in combination with HCTZ, bisoprolol, valsartan and losartan alone or in combination with HCTZ were added in 2004 and 2005. The total rate of hospital admissions for major cardiovascular events decreased by 18.2%. The utilization pattern was improved in 2005, showing a decrease in the number of hospital admissions for major cardiovascular events.

cardiovascular drugs, utilization, ATC/DDD methodology

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

65 (2)

2010.

193-201

objavljeno

0001-5385

10.2143/AC.65.2.2047053

Povezanost rada

Javno zdravstvo i zdravstvena zaštita

Poveznice
Indeksiranost